MaaT013: Positive Topline Phase 3 results

See more

Enhancing Survival Through Innovative Immune Modulation

We are a clinical-stage microbiome therapeutics company
aiming to improve survival in cancer.

Our strengths

A full ecosystem approach

Oncology focused

AI-Powered Drug Development

cGMP Versatile Manufacturing Capacities

Latest News

March 27, 2025

March 27, 2025: MaaT Pharma Completes a Capital Increase of €13 Million with Historical Shareholders and Announces 2024 Annual Results

March 18, 2025

March 18, 2025: MaaT Pharma Announces Positive Outcomes from Final DSMB Meeting for Pivotal Phase 3 Clinical Trial Evaluating MaaT013 in Acute Graft-versus-Host Disease

March 11, 2025

March 11, 2025: MaaT Pharma Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for MaaT013

Like what you see? See more posts

Our upcoming events

Event
March 28, 2025

EBMT – 51st Annual Meeting

• March 30 to April 2, 2025 – 51st Annual Meeting of the EBMT
MaaT Pharma
Event
March 28, 2025

Kempen – Life Sciences Conference

• April 1-3, 2025 – Van Lanschot Kempen Conferences, Amsterdam
MaaT Pharma
Event
March 28, 2025

AACR Annual Meeting 2025

• April 25-30, 2025 – AACR Annual Meeting, Chicago, IL
MaaT Pharma

Join the MaaT Pharma adventure!

Bring your talents, your passion and join an inclusive, creative, and multidisciplinary team. We aim to leverage the potential of microbiome to improve the treatment of patients with cancer.

Learn more about our values, our environment and see what we have to offer to you!

Careers